The primary aim of this study was to retrospectively evaluate the safety and efficacy of CsA in 1 0 0 the treatment of CH. A secondary aim was to identify if any factors previously shown to have 1 0 1 prognostic significance; such as, the presence of ascites, 6,41 clinical score, 18 1 0 2 hyperbilirubinemia, 6,42 hypoalbuminemia, 6, 21 or prolongations in prothrombin time University between the years 2010-2017 were reviewed. Dogs were included if they underwent 1 1 1 an ultrasound guided, laparoscopic, or surgical liver biopsy and were diagnosed with CH by a 1 1 2 board-certified veterinary pathologist. Patient presentation, diagnostic test results, liver 1 1 3 histopathology reports, and treatment response to cyclosporine were reviewed by one of two 1 1 4 board certified internists (DCT, CLW) to ensure adherence to WSAVA (World Small Animal 1 1 5 Veterinary Association) histologic criteria and limit inclusion to dogs with presumed idiopathic 1 1 6 CH. 8 Dogs with exposure to chronic hepatotoxic drugs/supplements or evidence of systemic 1 1 7 infectious disease were excluded. Dogs with elevated hepatic copper levels (> 1500 ug/g dry 1 1 8 weight) were included only if hepatic copper reduction therapy with penicillamine, zinc and/or a 1 1 9 copper restricted diet had not normalized ALT prior to initiation of CsA. Dogs that received 1 2 0 antibiotics or concurrent immunosuppressive medications were included as long as the 1 2 1 antimicrobial or immunomodulatory therapy had failed to achieve remission (normalization of 1 2 2 ALT) prior to initiation of CsA. It was not required that any of the copper reduction, 1 2 3 antimicrobial, or immunosuppressive therapies be administered for a specific duration of time. However, dogs that received less than 2 weeks of CsA treatment were excluded due to inability 1 2 5 to evaluate medication efficacy with the short duration of treatment. total bilirubin were collected pre-treatment at t=0 and at sequential time points when the patient 1 4 7 was rechecked. Since dogs were re-evaluated at variable time points, the data was categorized 1 4 8 into seven time intervals after baseline 0: 1 (2-4 weeks), 2 (1-3 months), 3 (3-6 months), 4 (6-9 1 4 9 months), 5 (9-12 months), 6 (1-2 years), and 7 (> 2 years). If more than one dataset was available 1 5 0 per time interval, the more complete and/or recent dataset was used. Due to variations in biochemical absolute value except for albumin, was converted to factor times the upper limit 1 5 5 (xULN) of normal to standardize the data. Albumin values were converted to factor times the 1 5 6 lower limit of normal (xLLN). The dose of CsA (mg/kg/day) and duration of therapy (months suspected to be associated with CsA administration; such as inappetence, vomiting, diarrhea, 1 5 9 gingival hyperplasia, secondary infections, hirsutism, papillomatosis, neoplasia, nephrotoxicity, and of those, dogs that achieved remission again after a dose increase were also recorded. Outcomes for each dog were categorized as alive, lost to follow up, death, or euthanized due to 1 7 1 hepatic or non-hepatic disease. Outcome data for each dog was obtained via retrospective 1 7 2 medical record review. Descriptive statistics were performed for the following variables: age (years), gender, breed, Continuous outcome liver parameter data for serum ALP, ALT, AST, GGT, bilirubin were 1 8 5 assessed for normality with a Shapiro-Wilk test. If the data was not normally distributed, a log intervals for each liver parameter. The impact of each clinical factor on the probability of remission was analyzed. A Fisher's exact test was used to assess the impact of the categorical variables (hepatic copper >1000ug/g, gender, Wilcoxon Two-Sample test was used to examine the effect of non-parametric continuous 1 9 7 variables; such as clinical scores and duration of therapy with remission. A Student's t-test was 1 9 8 used for assessment of parametric continuous variables (age, weight, and pre-treatment ALT 1 9 9
[xULN]). Likelihood of remission was also analyzed with a Cox Proportional Hazards Model of 2 0 0 survival analysis. Dogs that did not achieve remission or were lost to follow up were censored in 2 0 1 the analysis. Hazard ratios were calculated for each clinical factor. A log-rank test was used to All statistical analyses were performed by a statistician using a commercial software package. c Forty-eight dogs were included in the study of which 26/48 (54%) were female spayed, 20/48 2 0 8 (42%) were male castrated, and 2/48 (4%) were male intact. Median age was 8.5 years (range, 2 0 9 0.7-14 years). Median weight was 19.4 kg (range, 2.2-45kg). Twenty-two different breeds were 2 1 0 represented: mixed breed (12), Labrador retriever (10), standard poodle (4), Brittany spaniel (2), 2 1 1 Maltese (2), golden retriever (1), fox terrier (1), English springer spaniel (1), Scottish terrier (1), 2 1 2 pug (1), miniature pinscher (1), Pomeranian (1), beagle (1), Havenese (1), Italian greyhound (1), 2 1 3 beagle (1), Staffordshire terrier (1), basenji (1), wheaten terrier (1), bichon frise (1), ocherese (1), 2 1 4
Yorkshire terrier (1), Doberman pinscher (1). Biopsies were performed laparoscopically (39/48), 2 1 5 via ultrasound guidance (6/48), and surgically (3/48). All dogs were administered a microemulsified form of CsA d approved for use in dogs. Only one 2 1 9 dog was switched to an unknown brand generic CsA after the dog attained remission and the dog 2 2 0 remained in remission even after the change in medication. Forty-three of 48 (90%) dogs were 2 2 1 on concurrent hepatoprotectants; such as ursodiol (60%, 29/48), s-adenosylmethionine e (79%, 2 2 2 38/48), vitamin E (29%, 14/48), and/or silybin (2%, 1/48). Nineteen of 48 dogs (40%) received a 2 2 3 course of antibiotic therapy (combinations or monotherapy of amoxicillin, clindamycin, 2 2 4 amoxicillin/clavulanic acid, metronidazole, and/or enrofloxacin) prior to or shortly after the liver 2 2 5 biopsy was performed. Twelve dogs (25%) were on prednisolone prior to CsA therapy and were 2 2 6 tapered off corticosteroids completely before (2/12) or within 6 months of CsA initiation (10/12). Of the 12 dogs, one was on azathioprine concurrently, which was tapered and discontinued 2 2 8 before starting CsA. Another dog was on mycophenolate for immune-mediated polyarthritis 1 1 when she was diagnosed with CH, but the drug was ultimately tapered and discontinued. One 2 3 0 dog received a single dose of dexamethasone in the hospital. Seven dogs were treated with 2 3 1 penicillamine prior to starting CsA. One dog was started on losartan and one on colchicine. Three dogs were on therapy for ascites (spironolactone +/-furosemide). Type III P-values showed the overall effect of CsA on each liver parameter. The fold increases 2 7 5 over the ULN for serum ALP, ALT, and AST (type III P < 0.0001) and for serum GGT (type III 2 7 6 P = 0.002) were significantly decreased post-treatment compared to baseline, but were not 2 7 7 significantly different for xLLN albumin (type III P = 0.21). When CsA dose was held constant 2 7 8
to remove the effect of this variable, the fold increases over ULN for serum ALP, ALT, AST, and GGT remained significantly decreased post-treatment (Type III P-values in Table 1 ). No clinical or biochemical factor examined was significantly associated with remission ( that the probability of attaining remission was not impacted by ascites, hyperbilirubinemia, 2 8 5 hepatic Cu > 1000ug/g, or prolongation of PT/aPTT (Table 2 ). Median clinical score was 1.5 2 8 6 (range 0-7). Clinical score did not significantly differ between dogs that achieved remission and 2 8 7 those that did not (p = 0.61). Institution (p = 0.71), age (p = 0.87), gender (p = 0.83), weight (p = 2 8 8 0.48), pre-treatment xULN ALT (p = 0.67), duration of therapy (p = 0.74), and starting CsA dose 1 4
The most common adverse effects associated with CsA therapy were gastrointestinal signs in 2 9 7 18/48 (38%) including hyporexia, vomiting, and/or diarrhea (Table 3) . Seventeen of 18 dogs Three dogs were diagnosed with lymphoma. One had leukemic lymphoma with metastasis to the 3 0 9 liver, spleen, heart, lymph nodes, lung, and glomeruli on necropsy 8 months after starting CsA. The second dog had lymphoblasts on analysis of peritoneal effusion 19 months after starting 3 1 1
CsA. The third dog was diagnosed with multicentric lymphoma 6 months after starting CsA. Cyclosporine doses at the time of lymphoma diagnosis were 4.5mg/kg/day, 2.9mg/kg/day, and 3 1 3 3.7mg/kg/day, respectively for each dog. All dogs had evidence of lymphoplasmacytic infiltrates 3 1 4 on their initial liver biopsies, but no evidence of lymphoma. Two dogs experienced acute kidney injury 2 and 4 years after being on CsA, respectively. In both dogs, an etiology was not identified, but in the first dog, a necropsy showed severe chronic 3 1 8 interstitial nephritis and fibrosis with glomerulosclerosis. Survival outcome at the last available time-interval (range, 24-65 months) were as follows: alive have been a type II error due to small sample size and the mild degree of hypoalbuminemia. Hypoalbuminemia was present in only 6 dogs in this study of which only 2 had markedly 3 5 2 decreased albumin levels (1.6 g/dL and 1.8 g/dL). Although not statistically significant, serum The failure of remission in 21% of the dogs in this study could be explained by the individual 3 5 6 variability in the pharmacology and pharmacodynamic response to CsA that is known to exist in There were 4 cases with positive liver cultures. These cases were treated with appropriate 4 1 3 antibiotics; however, remission was not achieved with antibiotic therapy alone. These cases 4 1 4 eventually responded to CsA administration, which suggests that the primary etiology was 4 1 5 immune-mediated and not infectious. In some cases, these bacteria could have been 4 1 6 contaminants or opportunistic infections rather than primary pathogens. In future studies, This study had several limitations. introduced variability in the final diagnosis. Due to this limitation, we did not assess the effect of were converted to xULN or LLN in an attempt to standardize the data. In humans, the diagnostic criteria for autoimmune hepatitis are clearly established and scored In conclusion, this study demonstrated that CsA is a well-tolerated and potentially effective 4 5 6 medication in normalizing serum liver enzymes and total bilirubin in dogs with idiopathic CH. Previously reported poor prognostic factors in CH did not affect the ability of CsA to induce 4 5 8 remission. These findings provide further evidence that in some dogs, CH is immune-mediated. Further prospective studies will be necessary to determine whether CsA therapy results in Cox proportional hazards model of survival analyses were performed. No factor examined was significantly associated with remission.
The number and percentage of dogs with each clinical factor is listed. The number of dogs with each clinical factor that attained remission is also shown. 
